Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hvsen Biotechnology Co., Ltd. (300871.SZ)
CNY24.30
+0.05 (+0.21%)
CN SHZ Healthcare Biotechnology
Address
No.208 Zhangbai Road 430042
Wuhan, CN
Wuhan, CN
CEO
Jie Han
Website
whhsyy.com
IPO
2020-08-24
ISIN CNE1000047H6
Description
Hvsen Biotechnology Co., Ltd. is a company based in Wuhan, China, that focuses on the global research, development, and manufacturing of macrolide active pharmaceutical ingredients (APIs) and finished drug products. The company's diverse product portfolio features tylvalosin, offered in both raw material form and various preparations, along with florfenicol preparations and a broader selection of other macrolide-based offerings. Additionally, Hvsen produces a range of veterinary pharmaceuticals, available as both raw ingredients and finished drugs, alongside traditional Chinese medicine extracts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY24.30
+0.05 (+0.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
9M
Beta
0.60
Float Shares
106.47M
Free Float %
52.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.37% | -7.32% | -20.05% | -23.54% | +6.70% | +1.35% | -5.78% | +23.66% | -51.98% | -49.04% | -49.04% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
24.30
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.01
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+40.1% ★ Q1'26: +14.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+1,141.7% ★ Q1'26: +52.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+7.3% Q1'26: -3.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+18.0% ★ Q1'26: +19.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+13.9% ★ Q1'26: +14.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+22.0% Q1'26: +13.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.47× ★ Q1'26: 1.72× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
996.22M
est: 1.03B (-3.1%)
|
1.02B
est: 1.01B (+1.6%)
|
1.02B
est: 1.01B (+1.3%)
|
1.20B
est: 1.24B (-2.9%)
|
1.68B
est: 2.14B (-21.3%)
|
1.98B
1.98B – 1.98B
-7.3% YoY
|
2.58B
2.58B – 2.58B
+30.1% YoY
|
3.02B
3.02B – 3.02B
+17.2% YoY
|
| EBITDA |
182.25M
est: 172.05M (+5.9%)
|
138.10M
est: 167.80M (-17.7%)
|
161.05M
est: 167.80M (-4.0%)
|
127.18M
est: 205.97M (-38.3%)
|
422.63M
est: 355.78M (+18.8%)
|
329.95M
329.95M – 329.95M
-7.3% YoY
|
429.27M
429.27M – 429.27M
+30.1% YoY
|
502.92M
502.92M – 502.92M
+17.2% YoY
|
| EBIT |
153.70M
est: 104.84M (+46.6%)
|
75.53M
est: 92.54M (-18.4%)
|
40.66M
est: 92.54M (-56.1%)
|
14.04M
est: 113.58M (-87.6%)
|
302.27M
est: 196.20M (+54.1%)
|
181.96M
181.96M – 181.96M
-7.3% YoY
|
236.73M
236.73M – 236.73M
+30.1% YoY
|
277.35M
277.35M – 277.35M
+17.2% YoY
|
| Net Income |
132.87M
est: 69.67M (+90.7%)
|
52.71M
est: -62.21M (+184.7%)
|
16.78M
est: -62.21M (+127.0%)
|
-20.16M
est: -24.28M (+17.0%)
|
253.16M
est: 180.09M (+40.6%)
|
311.62M
311.62M – 311.62M
+73.0% YoY
|
408.75M
408.75M – 408.75M
+31.2% YoY
|
479.57M
479.57M – 479.57M
+17.3% YoY
|
| SGA |
88.49M
est: 56.53M (+56.5%)
|
101.96M
est: 90.30M (+12.9%)
|
131.29M
est: 90.30M (+45.4%)
|
118.69M
est: 110.83M (+7.1%)
|
54.18M
est: 191.45M (-71.7%)
|
177.55M
177.55M – 177.55M
-7.3% YoY
|
230.99M
230.99M – 230.99M
+30.1% YoY
|
270.63M
270.63M – 270.63M
+17.2% YoY
|
| EPS |
0.80
est: 0.42 (+90.5%)
|
0.32
est: -0.31 (+204.1%)
|
0.10
est: -0.31 (+132.5%)
|
-0.12
est: -0.12 (+0.0%)
|
1.25
est: 0.89 (+40.4%)
|
1.54
1.54 – 1.54
+73.0% YoY
|
2.02
2.02 – 2.02
+31.2% YoY
|
2.37
2.37 – 2.37
+17.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
590.66M
OE per share TTM
3.17
Owner's Yield
13.98%
Maintenance CapEx ratio
7.45%
Maint CapEx / Avg PPE
110.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.93% | 655.6K | 0.95% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
283.0K
Shares Outstanding
201.78M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hongxia Li | Director of Warehousing & Logistics Data and Supervisor | — | female |
| Hujie Yu | Deputy General Manager | — | male |
| Jie Han | Rotating General Manager | — | male |
| Jinbin Huang | Deputy General Manager | — | male |
| Kaijie Yang | Deputy GM & Chief Financial Officer | — | male |
| Qingfeng Wang | Board Secretary | — | male |
| Qiongbi Luo | Accounting Supervisor | — | — |
| Shuo Li | Deputy General Manager | — | male |
| Wenge Ding | Product & Technical Service Director and Supervisor | — | male |
| Zexiang Liu | Director & Assistant to the GM | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300871.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
